Navigation Links
Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
Date:6/2/2009

eclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. BiTE antibodies targeting CEA, MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of blinatumomab and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with relianc
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
2. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
3. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
4. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
5. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
6. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
7. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
8. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
9. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
10. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
11. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... USA (PRWEB) August 27, 2014 Scientists, ... month for SPIE Laser Damage 2014 symposium. ... materials for high-power lasers will run 14-17 September. The ... for optics and photonics . , The premier conference ... understanding laser damage to optical materials will engage researchers ...
(Date:8/28/2014)... Earlier this month, a report ... with the U.S. Air Force on the performance of ... that this type of fuel made from mustard seeds, ... important to America’s Eco friendly future. In fact, every ... to become independent of foreign oil over the next ...
(Date:8/28/2014)... 28, 2014 Supplementing their complete ... promotion for Eppendorf Safe Lock Centrifuge Tubes ... the highest quality tubes at an affordable price. ... customers doing chemical, medical, pharmaceutical, and life science ... not regularly able to afford Eppendorf products. , ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... N.J., July 21 BioNeutral Group, Inc. ("BioNeutral") (OTC ... Science Company announced today that at ATS Labs using ... Antimicrobial passed the difficult Quantitative Disk Carrier test ... difficile (C.diff) present in this test ...
... , , PALO ALTO, Calif., July 21, ... third quarter of its fiscal year 2009 after 1:00 p.m. Pacific Time ... of its investor conference call to review those quarterly results is scheduled ... , That live webcast can be accessed from Varian, ...
... , , KENILWORTH, N.J., July 21 ... for the 2009 second quarter. , , ... given us the strength to again power through tough challenges - delivering ... Fred Hassan, chairman and CEO. , , ...
Cached Biology Technology:BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 2BioNeutral's Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing. 3Schering-Plough Reports Financial Results for 2009 Second Quarter 2Schering-Plough Reports Financial Results for 2009 Second Quarter 3Schering-Plough Reports Financial Results for 2009 Second Quarter 4Schering-Plough Reports Financial Results for 2009 Second Quarter 5Schering-Plough Reports Financial Results for 2009 Second Quarter 6Schering-Plough Reports Financial Results for 2009 Second Quarter 7Schering-Plough Reports Financial Results for 2009 Second Quarter 8Schering-Plough Reports Financial Results for 2009 Second Quarter 9Schering-Plough Reports Financial Results for 2009 Second Quarter 10Schering-Plough Reports Financial Results for 2009 Second Quarter 11Schering-Plough Reports Financial Results for 2009 Second Quarter 12Schering-Plough Reports Financial Results for 2009 Second Quarter 13Schering-Plough Reports Financial Results for 2009 Second Quarter 14Schering-Plough Reports Financial Results for 2009 Second Quarter 15Schering-Plough Reports Financial Results for 2009 Second Quarter 16Schering-Plough Reports Financial Results for 2009 Second Quarter 17Schering-Plough Reports Financial Results for 2009 Second Quarter 18Schering-Plough Reports Financial Results for 2009 Second Quarter 19Schering-Plough Reports Financial Results for 2009 Second Quarter 20Schering-Plough Reports Financial Results for 2009 Second Quarter 21Schering-Plough Reports Financial Results for 2009 Second Quarter 22Schering-Plough Reports Financial Results for 2009 Second Quarter 23Schering-Plough Reports Financial Results for 2009 Second Quarter 24Schering-Plough Reports Financial Results for 2009 Second Quarter 25Schering-Plough Reports Financial Results for 2009 Second Quarter 26Schering-Plough Reports Financial Results for 2009 Second Quarter 27
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... number of studies have shown that excessive ... of Parkinson,s disease. Previous studies from Chunyan ... in China have shown that baicalin prevented ... divalent metal transporter 1 expression, and increased ... of rotenone-induced Parkinson,s disease rats. However, the ...
(Date:8/27/2014)... of seven hours ago the Happy Camp Complex of ... California, the July complex had consumed 35,530 as of ... fires on the Happy Camp Ranger District of the ... area on August 11, 2014. All but three of ... is a list of contained fires and their size ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... your body is telling you that your pace feels a little ... A new study, published online March 18 in the ... human running varies with speed and that each individual has an ... distance with the least effort. The result debunks the ...
... millions of people with diseases that starve eye tissue ... procedure being developed by researchers at Oak Ridge National ... of Tennessee. The technique uses a new class ... tissue being deprived of oxygen because of restricted blood ...
... of the benefits of cooling strategies to protect the ... to a wealth of cutting edge research, prime examples ... of Journal of Neurotrauma , a peer-reviewed journal ... The issue will be available free online at ...
Cached Biology News:Optimum running speed is stride toward understanding human body form 2ORNL, Southern Cal set sights on preventing blindness 2Therapeutic hypothermia is promising strategy to minimize tissue damage 2
... 25-Hydroxy Vitamin D kit is an ... of 25-hydroxyvitamin D (25-OH D) and ... or plasma. Our patented DIRECT assay ... precipitation and centrifugation and therefore facilitates ...
... The IDS Corticosterone kit is a competitive ... corticosterone in mouse or rat serum or ... sole, corticosteroid in rats and mice, and ... birds and reptiles. Most mammals produce both ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Biology Products: